Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Biosimilars in oncology: EHA 2017 session on rituximab

Bertrand Coiffier • 22 Jun 2017
EHA 2017
Rituximab

Bertrand Coiffier, MD from the Centre Hospitalier Lyon-Sud, Pierre-Bénite, France discusses the session on the biosimilar rituximab held at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. Prof. Coiffier explains some of the key topics discussed during the session, including the advantages of using biosimilars in practice, the rationale for their development biosimilars and the clinical evidence to date.

More from Bertrand Coiffier

2:40
Understanding biosimilars
Bertrand Coiffier • 22 Jun 2017
3:27
Why we need novel strategies for diffuse large B-cell lymphoma
Bertrand Coiffier • 22 Jun 2017
0:39
Biosimilars: informing patients and physicians
Bertrand Coiffier • 22 Jun 2017
1:30
ASH 2014: Phase III Lyma trial of rituximab maintenance after ASCT in mantle cell lymphoma
Bertrand Coiffier • 5 Dec 2014
The content of VJHemOnc is intended for healthcare professionals